logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Facebook (FB) announced Thursday it has agreed to release advertisements purchased by Russians in an effort to influence last year's election to congressional investigators. Calling North Korean nuclear weapons and missile development a grave threat to global peace and security, President Donald Trump announced Thursday he has signed an executive order seeking to crack down on trade with the reclusive communist nation. Come weekends and the ride sharing company Lyft in association with the beer brand Budweiser will offer free travel for short distances. The program is aimed at discouraging drunk driving on holidays. The offer of 150,000 free trips will be available in 10 states, all through the year.
comments powered by Disqus
Follow RTT